MYOS RENS Technology to Present at the MicroCap Conference April 10 in New York City at the Essex House

CEDAR KNOLLS, N.J., April 3, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin^®, the natural product that helps build lean muscle in conjunction with resistance training, announced that the Company's Chief Executive Officer, Joseph Mannello, will present at the MicroCap Conference on Tuesday, April 10th at 12:30 p.m. Eastern Time at the Essex House in New York City. Mr. Mannello will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

"We are excited about the opportunity to meet with investors to discuss our recent business developments," said Mr. Mannello. "These include our growing portfolio of research projects to further explore the benefits of our proprietary ingredient, Fortetropin^®; our new Fortetropin^®-based pet product; and additional brand development initiatives that position us to tap into the $28 billion-and-rising fitness and sports nutrition market, as well as the active senior population which is expected to double over the next 30 years."

To request free registration, please go to the conference website (https://microcapconf.com/), and click the "Registration" button.

About MYOS RENS Technology Inc. 

MYOS RENS Technology Inc. (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based bionutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin^®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin^® has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. MYOS believes Fortetropin^® has the potential to redefine existing standards of physical health and wellness. For more information, please visit www.MYOSRENS.com.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the successful launch of our products, including Qurr^® products, the success of our research and development, the results of the clinical evaluation of Fortetropin^® and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate revenue and cash flow from sales of our products, the ability to continue increasing our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances afterthe date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com

View original content with multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-to-present-at-the-microcap-conference-april-10-in-new-york-city-at-the-essex-house-300623787.html

SOURCE MYOS RENS Technology Inc.